4DMedical's (ASX:4DX) CT:VQ imaging technology received CE Mark certification for commercial use across the European Union, according to a Friday filing with the Australian bourse.
The company also received firm commitments to raise AU$83 million through the placement of about 14.1 million shares at AU$5.90 apiece, the filing said.
Proceeds will be used to fund the commercial launch of CT:VQ in Europe and international markets, support clinical integration for new customers, and strengthen the balance sheet, per the filing.
Shares rose nearly 10% in morning trade Friday and earlier reached an all-time high.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments